131 related articles for article (PubMed ID: 31500459)
1. Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.
Radovanovic D; Contoli M; Marco FD; Sotgiu G; Pelaia G; Braido F; Corsico AG; Micheletto C; Rogliani P; Scichilone N; Saderi L; Santus P; Solidoro P
COPD; 2019 Aug; 16(3-4):215-226. PubMed ID: 31500459
[TBL] [Abstract][Full Text] [Related]
2. The effect of comorbidities on COPD assessment: a pilot study.
Weinreich UM; Thomsen LP; Bielaska B; Jensen VH; Vuust M; Rees SE
Int J Chron Obstruct Pulmon Dis; 2015; 10():429-38. PubMed ID: 25750525
[TBL] [Abstract][Full Text] [Related]
3. Impact of using the new GOLD classification on the distribution of COPD severity in clinical practice.
Hernández M; García G; Falco J; García AR; Martín V; Ibarrola M; Quadrelli S
Int J Chron Obstruct Pulmon Dis; 2018; 13():351-356. PubMed ID: 29403272
[TBL] [Abstract][Full Text] [Related]
4. Demographic and Clinical Characteristics of COPD Patients at Different Blood Eosinophil Levels in the UK Clinical Practice Research Datalink.
Landis S; Suruki R; Maskell J; Bonar K; Hilton E; Compton C
COPD; 2018 Apr; 15(2):177-184. PubMed ID: 29558236
[TBL] [Abstract][Full Text] [Related]
5. Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011.
Marçôa R; Rodrigues DM; Dias M; Ladeira I; Vaz AP; Lima R; Guimarães M
COPD; 2018 Feb; 15(1):21-26. PubMed ID: 29161163
[TBL] [Abstract][Full Text] [Related]
6. 2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group.
Högman M; Sulku J; Ställberg B; Janson C; Bröms K; Hedenström H; Lisspers K; Malinovschi A
Int J Chron Obstruct Pulmon Dis; 2018; 13():165-173. PubMed ID: 29379281
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
Song JH; Lee CH; Kim JW; Lee WY; Jung JY; Park JH; Jung KS; Yoo KH; Park YB; Kim DK
Int J Chron Obstruct Pulmon Dis; 2017; 12():2455-2464. PubMed ID: 28860740
[TBL] [Abstract][Full Text] [Related]
8. The distribution of COPD in UK general practice using the new GOLD classification.
Haughney J; Gruffydd-Jones K; Roberts J; Lee AJ; Hardwell A; McGarvey L
Eur Respir J; 2014 Apr; 43(4):993-1002. PubMed ID: 24176990
[TBL] [Abstract][Full Text] [Related]
9. The PLATINO study: description of the distribution, stability, and mortality according to the Global Initiative for Chronic Obstructive Lung Disease classification from 2007 to 2017.
Menezes AM; Wehrmeister FC; Perez-Padilla R; Viana KP; Soares C; Müllerova H; Valdivia G; Jardim JR; Montes de Oca M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1491-1501. PubMed ID: 28553101
[TBL] [Abstract][Full Text] [Related]
10. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.
Vestbo J; Vogelmeier CF; Small M; Siddall J; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2019; 14():853-861. PubMed ID: 31114183
[No Abstract] [Full Text] [Related]
11. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry.
Kobayashi S; Hanagama M; Ishida M; Sato H; Ono M; Yamanda S; Yamada M; Aizawa H; Yanai M
Int J Chron Obstruct Pulmon Dis; 2018; 13():3947-3955. PubMed ID: 30584294
[TBL] [Abstract][Full Text] [Related]
12. Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study.
Crapo JD; Gupta A; Lynch DA; Turner AM; Mroz RM; Janssens W; Ludwig-Sengpiel A; Koegler H; Eleftheraki A; Risse F; Diefenbach C
Respir Res; 2023 Nov; 24(1):290. PubMed ID: 37978492
[TBL] [Abstract][Full Text] [Related]
13. Subgroup analysis reveals higher reliability of the new comprehensive evaluation of Global Initiative for Chronic Obstructive Lung Disease 2019.
Dai Z; Zeng H; Cui Y; Chen P; Chen Y
Sci Rep; 2022 Jan; 12(1):757. PubMed ID: 35031681
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of asthma-COPD overlap syndrome.
Joo H; Han D; Lee JH; Rhee CK
Int J Chron Obstruct Pulmon Dis; 2017; 12():697-703. PubMed ID: 28260876
[TBL] [Abstract][Full Text] [Related]
15. The revised GOLD 2017 COPD categorization in relation to comorbidities.
Kahnert K; Alter P; Young D; Lucke T; Heinrich J; Huber RM; Behr J; Wacker M; Biertz F; Watz H; Bals R; Welte T; Wirtz H; Herth F; Vestbo J; Wouters EF; Vogelmeier CF; Jörres RA
Respir Med; 2018 Jan; 134():79-85. PubMed ID: 29413512
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
17. The association between objectively measured physical activity and morning symptoms in COPD.
van Buul AR; Kasteleyn MJ; Chavannes NH; Taube C
Int J Chron Obstruct Pulmon Dis; 2017; 12():2831-2840. PubMed ID: 29042764
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
19. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
Rebordosa C; Plana E; Aguado J; Thomas S; García-Gil E; Perez-Gutthann S; Castellsague J
Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):126-133. PubMed ID: 29740896
[TBL] [Abstract][Full Text] [Related]
20. GOLD Classification of COPD: Discordance in Criteria for Symptoms and Exacerbation Risk Assessment.
Mittal R; Chhabra SK
COPD; 2017 Feb; 14(1):1-6. PubMed ID: 27723367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
